Sintx Technologies (SINT) AI Stock Analysis

• Market Cap: $13.75M
• Dividend Yield: N/A
• Average Volume (3M): 148.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: -60.89%
• EPS Growth: 94.49%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -22.09
• Shares Outstanding: 3,851,956
• 10 Day Avg. Volume: 107,243
• 30 Day Avg. Volume: 148,787
• PEG Ratio: <0.01
• Price to Book (P/B): 0.67
• Price to Sales (P/S): 0.90
• P/FCF Ratio: -0.28
• Enterprise Value/Market Cap: 0.19
• Enterprise Value/Revenue: 2.13
• Enterprise Value/Gross Profit: 4.25
• Enterprise Value/Ebitda: -0.29
• 1Y Price Target: $25.00
• Price Target Upside: 600.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $3.00 ▼(-15.97% Downside)

Sintx Technologies' overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative cash flows. The technical analysis indicates a bearish trend, and the valuation metrics are unattractive due to the negative P/E ratio. These factors collectively result in a low overall stock score.

Positive Factors

Strategic Partnerships

The partnership with Evonik enhances SINTX's manufacturing capabilities, enabling the production of advanced, patient-specific implants. This strategic move could significantly expand SINTX's market reach and product offerings, supporting long-term growth in the medical device sector.

Intellectual Property

The new patent strengthens SINTX's competitive position by protecting its unique antipathogenic technology. This enhances licensing opportunities and broadens potential applications, positioning the company as a leader in infection-resistant materials across various medical and industrial sectors.

Regulatory Approvals

The FDA clearance allows SINTX to enter the U.S. market for reconstructive foot and ankle surgery. This regulatory milestone validates SINTX's technology and opens new revenue streams, supporting long-term growth and market expansion in the orthopedic sector.

Negative Factors

Declining Revenues

The significant drop in revenue highlights ongoing financial challenges. Sustained revenue declines can impact cash flow and limit the company's ability to invest in growth initiatives, posing a risk to long-term financial health and stability.

Negative Cash Flow

Persistent negative cash flow indicates financial strain, limiting SINTX's ability to fund operations and growth. This could necessitate additional financing, increasing financial risk and potentially diluting shareholder value over time.

High Operating Losses

High operating losses reflect inefficiencies and cost management issues. Sustained losses can erode shareholder equity and hinder the company's ability to achieve profitability, impacting long-term viability and competitive positioning.

Sintx Technologies Business Overview & Revenue Model

Company Description

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Sintx Technologies generates revenue through the sale of its silicon nitride-based products to healthcare and industrial clients. The company primarily earns money from licensing agreements, where it partners with medical device manufacturers to integrate its materials into their products. Additionally, Sintx may engage in direct product sales of its proprietary technology and components, providing a steady stream of income. Strategic partnerships with industry leaders in the medical field enhance its market reach and drive revenue growth, while ongoing research and development efforts aim to expand its product portfolio and attract new clients.

Sintx Technologies Financial Statement Overview

Summary

Sintx Technologies is facing significant financial challenges, with declining revenues, high operating losses, and negative cash flows. The balance sheet shows moderate leverage, but the negative return on equity highlights poor financial performance. The company needs to address its profitability and cash flow issues to improve its financial health.

Income Statement

Sintx Technologies has been experiencing declining revenues with a negative growth rate of -11.54% in the TTM. The company shows a significant net loss, with a net profit margin of -13.59% and an EBIT margin of -8.03%. Despite a decent gross profit margin of 50.04%, the overall profitability is severely impacted by high operating losses.

Balance Sheet

The company's debt-to-equity ratio stands at 0.82, indicating moderate leverage. However, the return on equity is negative at -367.21%, reflecting poor returns for shareholders. The equity ratio is relatively stable, suggesting some balance in asset financing.

Cash Flow

Sintx Technologies has a negative operating cash flow, with a concerning operating cash flow to net income ratio of -1.69. The free cash flow to net income ratio is slightly better at 1.04, but the overall cash flow situation indicates financial strain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.22M	1.25M	2.63M	601.00K	606.00K	594.00K
Gross Profit	610.00K	435.00K	1.84M	336.00K	157.00K	119.00K
EBITDA	-9.07M	-9.61M	-6.60M	-11.06M	-8.63M	-6.53M
Net Income	-16.56M	-11.02M	-8.26M	-12.04M	-9.31M	-7.03M
Balance Sheet
Total Assets	11.36M	9.41M	15.37M	15.77M	21.84M	30.45M
Cash, Cash Equivalents and Short-Term Investments	6.25M	3.60M	3.34M	6.25M	14.27M	25.35M
Total Debt	3.39M	4.03M	4.76M	3.63M	2.91M	2.28M
Total Liabilities	7.30M	5.52M	6.59M	10.07M	4.64M	4.64M
Stockholders Equity	4.07M	3.89M	8.77M	5.70M	17.20M	25.80M
Cash Flow
Free Cash Flow	-7.64M	-9.33M	-14.64M	-11.67M	-13.87M	-9.47M
Operating Cash Flow	-7.35M	-8.64M	-14.12M	-10.26M	-10.13M	-9.11M
Investing Cash Flow	965.00K	-194.00K	-501.00K	-1.10M	-1.66M	1.75M
Financing Cash Flow	7.82M	9.09M	11.71M	3.34M	705.00K	30.93M

Sintx Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SINT, the sentiment is Negative. The current price of 3.57 is below the 20-day moving average (MA) of 3.70, below the 50-day MA of 3.65, and above the 200-day MA of 3.27, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 11.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SINT.

Sintx Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNON	49 Neutral	$12.22M	-0.40	-197.26%	―	-2.47%	91.23%
SSKN	44 Neutral	$7.83M	-0.51	-207.19%	―	-5.19%	-0.81%
CODX	42 Neutral	$14.99M	-0.26	-62.12%	―	-87.84%	29.16%
SINT	40 Underperform	$13.75M	-0.52	-204.04%	―	-60.89%	94.49%
HSDT	39 Underperform	$128.03M	>-0.01	―	―	87.45%	72.30%
HIND	37 Underperform	$22.97M	-0.02	-565.18%	―	-48.74%	89.18%

Sintx Technologies Corporate Events

Sintx Technologies Announces At The Market Offering

On October 3, 2025, SINTX Technologies entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock. This agreement allows for the sale of shares through an ‘at the market offering’ program, with Wainwright acting as the sales agent. The company is not obligated to sell any shares and can suspend the offering at any time. The agreement includes customary indemnification and contribution rights, and the shares will be issued under the company’s shelf registration statement filed with the SEC.

Sintx Technologies Enters Inducement Agreement for $3.8M

On September 8, 2025, SINTX Technologies, Inc. entered into an inducement agreement with certain holders of its existing warrants to purchase shares of common stock. The agreement involves the exercise of existing warrants and the issuance of new warrants, expected to generate approximately $3.8 million in gross proceeds for the company. The company plans to use these proceeds for general corporate purposes. The transactions are expected to close on or about September 9, 2025, subject to customary conditions.